by The global prurigo nodularis treatment market size reached USD 2.13 billion in 2023 and is predicted to attain around USD 3.17 billion by 2033, growing at a CAGR of 4.03% from 2024 to 2033.
Key Points
- The North America prurigo nodularis treatment market size accounted for USD 870 million in 2023 and is expected to attain around USD 1,300 million by 2033.
- North America dominated the market with the major market share of 41% in 2023.
- Asia Pacific is estimated to be the fastest growing during the forecast period of 2024-2033.
- By product type, the corticosteroids segment has held the biggest market share of 37% in 2023.
- By product type, the antihistamines segment is estimated to be the fastest growing during the forecast period.
- By distribution channel type, the retail pharmacies segment has contributed more than 42% of market share in 2023.
- By distribution channel type, the online pharmacies segment is expected to be the fastest growing during the forecast period.
Prurigo nodularis is a chronic skin condition characterized by the presence of intensely itchy nodules or bumps on the skin. The treatment market for prurigo nodularis is driven by the rising prevalence of this condition globally. Prurigo nodularis can be challenging to manage, and treatment options often focus on alleviating symptoms and improving quality of life for affected individuals. The market for prurigo nodularis treatments includes pharmaceuticals, topical therapies, and emerging biologic agents designed to target specific pathways involved in the disease process.
Get a Sample: https://www.precedenceresearch.com/sample/4279
Growth Factors
The growth of the prurigo nodularis treatment market is propelled by increasing awareness about this condition among healthcare providers and patients. As more research sheds light on the underlying mechanisms of prurigo nodularis, novel therapeutic approaches are being developed, fostering market growth. Additionally, the expanding elderly population, who are more susceptible to prurigo nodularis, contributes to market expansion.
Region Insights
The market for prurigo nodularis treatments exhibits variations across different regions. Developed countries with advanced healthcare systems typically have higher adoption rates for new treatments and therapies. However, the burden of prurigo nodularis is also significant in developing regions, where access to effective treatments may be limited due to socioeconomic factors.
Prurigo Nodularis Treatment Market Scope
| Report Coverage | Details |
| Prurigo Nodularis Treatment Market Size in 2023 | USD 2.13 Billion |
| Prurigo Nodularis Treatment Market Size in 2024 | USD 2.22 Billion |
| Prurigo Nodularis Treatment Market Size by 2033 | USD 3.17 Billion |
| Growth Rate from 2024 to 2033 | CAGR of 4.03% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product Type and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Prurigo Nodularis Treatment Market Dynamics
Drivers
Key drivers of the prurigo nodularis treatment market include the introduction of new pharmaceuticals targeting specific pathways implicated in the disease process. Advances in dermatology and immunology contribute to the development of biologic agents and targeted therapies, providing hope for improved outcomes in managing prurigo nodularis.
Opportunities
Opportunities in the prurigo nodularis treatment market lie in the development of more effective and well-tolerated therapies. There is a growing demand for treatments that not only reduce itching and inflammation but also address the underlying causes of prurigo nodularis. Collaborations between pharmaceutical companies and research institutions offer potential avenues for innovation and therapeutic breakthroughs.
Challenges
The prurigo nodularis treatment market faces challenges related to the complexity of the disease and the limited understanding of its pathogenesis. Additionally, accessing effective treatments can be difficult for patients in certain regions or healthcare systems. Regulatory hurdles and the high cost of developing and marketing new therapies also pose challenges to market growth.
Read Also: Medical Gas Market Size to Rise USD 32.47 Billion by 2033
Prurigo Nodularis Treatment Market Recent Developments
- In February 2023, Pfizer’s supplemental new drug applications (NDA) for abrocitinib (CIBINQO) was announced by the United States (U.S.) Food and Drug Application (FDA) for the treatment of serious atopic dermatitis, refractory, skin clearance, itching, severity, and disease extent for the 12 to less than 18 years of age group.
- In October 2023, new positive pruritus data for VTAMA Cream from their essential phase 3 trials was announced by a clinical-stage biopharmaceutical company, Dermavant Sciences (tapinarof). This is for children as young as two years old, and 1% of adults suffer from atopic dermatitis. It is also important to reduce itching, burning, redness, and itching.
- In February 2024, the Food and Drug Administration (FDA) accepted Galderma’s BLA (biological license application) for Nemolizumab to treat atopic dermatitis and prurigo nodularis.
Prurigo Nodularis Treatment Market Companies
- Bayer AG
- Celgene Corporation
- Glaxo Smith Kline plc
- Galderma Takeda Pharmaceuticals (Nestle Skin Health Company)
- Johnson & Johnson Services Inc.
- Merk & Co. Inc
- Novartis AG
- Pfizer Inc
- Sanofi SA
- Teva Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Company Inc
- VYNE Therapeutics Inc.
Segments Covered in the Report
By Product Type
- Antihistamines
- Capsaicin Cream
- Corticosteroids
- Emollients
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
